Gene therapy rollout: Australia next in line?
Krystal Biotech is ramping up its Australian commercialisation efforts for Vyjuvek, a topical gene therapy for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB).
To see the whole article, log in or create an account.